Navigation Links
Einstein researcher receives American Cancer Society Medal of Honor
Date:11/9/2010

November 5, 2010 (BRONX, NY) Albert Einstein College of Medicine of Yeshiva University researcher Jeffrey Pollard, Ph.D., has received the prestigious Medal of Honor in Basic Science from the American Cancer Society (ACS) in recognition of his research into the critical role the tumor microenvironment plays in modulating cancer behavior, specifically the role that members of the innate immune cells called macrophages play both in normal development and in promoting tumor progression. These macrophages could hold the key to more targeted cancer treatments.

Insights into how normal body cells support tumor growth have led the way to a new wave of research and the development of therapeutics specifically targeting the support cells in the body that can aid in tumor development. Dr. Pollard's research has found that when macrophages are removed from the tumor microenvironment, the risk of cancer progressing to malignancy is reduced and its spread from the primary tumor site to distant sites lessens.

"I think that one of the major components of the therapeutic arsenal as we go forward will be to combine chemo-therapeutic drugs with drugs that target macrophages so that they can no longer support the tumor's ability to be malignant," said Dr. Pollard. "Further it gives another opportunity for therapy by using vaccination against tumor antigens combined with altering macrophages from tumor promoting to tumor rejecting. It gives us another prong in the attack on cancer."

Dr. Pollard is deputy director of the Albert Einstein Cancer Center, director of the Center for Study of Reproductive Biology and Women's Health and the Louis Goldstein Swan Chair in Women's Cancer Research at Einstein. He is also professor in the departments of developmental and molecular biology and obstetrics & gynecology and women's health at Einstein and Montefiore Medical Center.

This award from the American Cancer Society, the nation's leading voluntary health organization and largest non-governmental investor in cancer research, represents the Society's highest honor in recognition of outstanding contributions to fighting cancer.

The award was presented at the American Cancer Society's annual meeting in Atlanta, GA. In addition to Dr. Pollard, the ACS recognized Joseph Fraumeni, M.D., M.Sc., for Cancer Control, and Patricia Ganz, M.D., for Clinical Research.

This is the second ACS Medal of Honor awarded to a researcher at the Albert Einstein Cancer Center. Susan Band Horwitz, Ph.D., received the Medal of Honor in 2008 for Clinical Research.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein receives $30 million to study protein form and function
2. Einstein designated an NIH Center of Excellence for aging research
3. Einstein receives $4 million to test HPV microbicide
4. Einstein researcher awarded prestigious cancer research grant
5. Einstein-Montefiore research tackles childhood obesity in the Bronx
6. Einstein researchers discover 2 new ways to kill TB
7. Einstein receives high-risk/high-reward cancer research funding
8. Einstein to develop anti-HIV drug delivery system
9. Einstein scientists move closer to a safer anthrax vaccine
10. Einstein researchers devise a fast and sensitive way to detect ricin
11. NIH funds research center for womens reproductive health at Einstein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their boarding ... ... biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at the ... to allow eligible Delta SkyMiles Members who are enrolled in CLEAR to ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... Palo Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... is set to take place on 7th and 8th June 2018 in San Francisco, ... and policy influencers as well as several distinguished CEOs, board directors and government officials ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
Breaking Biology Technology: